Table 1 Baseline characteristics of study participants
From: A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia
Variable | Total group (n = 144) | Arthritis (n = 43) | No arthritis (n = 101) | p value |
|---|---|---|---|---|
Time until end of follow-up (censoring or arthritis; months) | 60 (1–60) | 15 (0–60) | 60 (30–60) | <0.01 |
Age (years)* | 55 (11) | 54 (11) | 56 (12) | NS |
Males (%) | 23 | 28 | 21 | NS |
Disease activity | ||||
Tender joint count 53 | 0 (0–5) | 0 (0–2) | 0 (0–5) | NS |
Visual analogue scale pain | 29 (0–100) | 35 (0–100) | 26 (0–98) | NS |
Use of NSAIDs (%) | 29 | 35 | 26 | NS |
ESR (mm/hour) | 11 (0–34) | 11 (0–34) | 11 (1–31) | NS |
CRP (mg/l) | 2 (0–47) | 2 (0–47) | 3 (0–27) | NS |
Fulfilment of 2010 ACR/EULAR classification criteria for RA (%) | NA | 95 | 0 | NA |
14-3-3η results | ||||
Level (ng/ml) | 0.35 (0.03–20) | 0.95 (0.12–20) | 0.28 (0.03–20) | <0.01 |
≥0.19 ng/ml (%) | 71 | 86 | 64 | <0.01 |
≥0.40 ng/ml (%) | 45 | 58 | 40 | 0.04 |
≥0.80 ng/ml (%) | 33 | 51 | 24 | <0.01 |
RF results | ||||
Level (IU/ml) | 38 (1–1192) | 31 (1–383) | 40 (1–1192) | NS |
Positivity (%) | 63 | 61 | 63 | NS |
ACPA results | ||||
Level (AU/ml) | 108 (0–9860) | 455 (0–8710) | 59 (0–9860) | <0.01 |
Positivity (%) | 65 | 95 | 53 | <0.01 |